Galderma Commits $650M to US Manufacturing as Nemluvio Sales Soar

Galderma, the Swiss dermatology specialist, has announced a significant investment in US-based manufacturing, pledging to spend over $650 million through 2030. This move comes as the company reports booming sales of its newly approved drug Nemluvio and record-breaking revenue figures for the year.

US Manufacturing Investment and Expansion

Galderma's $650 million commitment will focus on tapping domestic contractors to produce Nemluvio and other skincare treatments in its portfolio. The investment includes plans to ramp up final assembly and packaging of Nemluvio in Florida through a local partner. Additionally, the company aims to bolster US contract production of its skincare treatments Alastin and Cetaphil.

This manufacturing initiative is part of Galderma's broader strategy to strengthen its US presence. The company recently opened its US headquarters in Miami and maintains an R&D hub in Boston, two facilities in the Dallas-Fort Worth area, and an outlet in Carlsbad, California.

Nemluvio's Market Success and Financial Impact

Nemluvio, an injected IL-31 treatment, has been a key driver of Galderma's recent financial success. In the first nine months of 2025, Nemluvio generated sales of $263 million, with $131 million coming in Q3 alone. This performance is particularly impressive considering the drug has only been on the market for 14 months.

Initially approved in the US for prurigo nodularis (PN) in August 2024, Nemluvio's indication was expanded to include eczema treatment in December of the same year. European regulators approved the drug for both indications in February 2025. While early sales were primarily for PN patients, Q3 saw atopic dermatitis sales overtake those for PN, indicating a growing market opportunity.

Financial Outlook and Market Position

Galderma's strong performance, driven by Nemluvio's success, has led the company to revise its annual growth guidance upward. The new projection ranges from 17% to 17.7%, a significant increase from the earlier 12% to 14% forecast. Through the first three quarters of 2025, Galderma has reported record revenue of $3.7 billion.

CEO Flemming Ornskov, M.D., noted that Nemluvio's uptake "continues to surpass expectations, underpinned by growing demand and increased access." The company is also making progress with other products, including the neuromodulator Relfydess for frown lines and crow's feet, which launched in Europe this year but faces delays in the US due to manufacturing issues.

As Galderma continues to expand its US operations and invest in domestic manufacturing, the company appears well-positioned to capitalize on the success of Nemluvio and strengthen its role as a leader in the dermatology market.